Brain tumors have long forced pathologists into a difficult balancing act. Under the microscope, many look alike at first glance. However, small molecular differences can separate a relatively manageable disease from one that demands urgent, aggressive treatment. Getting that distinction right often depends on specialized testing that can take days and costs hundreds of euros. Unfortunately, this kind of testing is still out of reach in many par…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.